MON, 26 November 2018
17:30 - 19:00	Welcome reception in the Dan Hotel
TUE, 27 November 2018
08:15 - 09:00	Registration
09:00 - 09:05	Opening
	Experimental Uveitis Models in 2018
09:05 - 09:25	Regulation of Th17 response by IL-17: implications for autoimmunity	Rachel Caspi
09:25 - 09:45	Lessons from experimental rat models for chronic and relapsing autoimmune uveitis	Gerhild Wildner
09:45 - 10:05	Of mice and men and women	James Rosenbaum
10:05 - 10:20	Discussion
	The Role of Microbiome in Uveitis
10:45 - 11:00	Welcome to the World of Microbiota	Nida Sen
11:00 - 11:18	Microbiome and the Eye-the good and the bad	Rachel Caspi
11:18 - 11:38	Microbiome and Tuberculosis	Florian Hoelzl​
11:38 - 11:56	Microbiome and HLA-B27	James Rosenbaum
11:56 - 12:16	Virome and the Eye	Jolanda D.F de Groot-Mijnes
12:16 - 12:30	Discussion
	Multimodal Imaging (MMI) for Inflammatory Outer Retinopathies
13:30 - 13:42	What have we learned from MMI about inflammatory outer retinopathies	Michal Kramer
13:42 - 13:54	Insights to outer retinopathies from OCTA and Adaptive Optics	Padmamalini Mahendradas
13:54 - 14:04	Clues for inflammation by MMI of rarest entities	Orly Gal-Or
14:04 - 14:16	Clinical application of Artificial Intelligence and Machine Learning	Noam Bresiz
14:16 - 14:26	The way to use Artificial Intelligence and machine learning in Uveitis Diagnosis	Antoine Brezin
14:26 - 14:36	How MMI changes our management of inflammatory outer retinopathies	Padmamalini Mahendradas
14:36 - 14:45	Discussion
15:15 - 16:15	Controversies
	1. Systemic vs intraocular steroid therapy for acute toxoplasmic retinochoroiditis	pro systemic: Emmett Cunningham pro intraocular: Rubens Belfort
	2. Biologics vs immunosuppressives as first line treatment for JIA-induced uveitis	pro Biologics: Athimalaipet V. Ramanan pro Immunosuppressives: Debra Goldstein
	3. Treatment of Behcet´s Disease: anti-TNF vs interferon alpha	pro: anti-TNF-alpha: Shiri Shulman pro: interferon alpha: Manfred Zierhut
	Progression Markers
16:15 - 16:25	Progression markers of Vogt Koyanagi Haradas Disease	Nobuyoshi Kitaichi
16:25 - 16:35	Biomarkers for increased risk of developing uveitis in JIA	Joke de Boer
16:35 - 16:45	Laser flare photometry can predict a recurrence in Behçet-uveitis	Nilüfer Yalcindag
16:45 - 17:00	Discussion
WED, 28 November 2018
08:30 - 09:00	Registration (new participants)
	Tuberculosis - From Infection to Inflammation
09:00 - 09:12	Immunology of general TB infection	Florian Hoelzl​
09:12 - 09:24	Immunology of ocular TB infection	Soumyava Basu
09:24 - 09:36	Update of the the COTS-studies	Reema Bansal
09:36 - 09:48	Clinical spectrum of “inflammatory” TB	Vasconcellos-Santos D​aniel
09:48 - 10:00	Quantiferon testing in endemic vs. non-endemic areas	Soon Phaik Chee
10:00 - 10:15	Discussion
	Preparing for Intraocular Surgery in Uveitis Patients
10:45 - 11:00	General principles of medical preparation for intraocular surgery in uveitis
11:00 - 11:15	Intra- and perioperative care during cataract surgery
11:15 - 11:30	Preparing for glaucoma drainage and vitrectomy in uveitis
11:30 - 12:30	Round Table	Moderator: Nicholas Jones Cristina Muccioli, Nisha Acharya, Matthias Becker
	Uveitis Related Macular Edema
13:30 -13:50	Differences between Uveitis macular edema and other etiologies	Francine Behar Cohen
13:50 - 14:00	Role of Cytokines in uveitis related CME	Marina Mesquida
14:00 - 14:15	Macular edema-what have the MUST trials taught us	Sue Lightman
14:15 - 14:30	Options for treatment of uveitis related CME	Marina Mesquida
14:30 - 14:40	Biologics and uveitic CME	Oren Tomkins
14:40 - 15:00	Discussion
	Future Protocols for Uveitis Trials
15:30 - 15:35	Introduction	Philip Murray
15:35 - 15:50	The Problem of outcome measurements in uveitis trials	Nisha Acharya
15:50 - 06:03	Clinical trials in uveitis-The Industry Perspective	Ron Neuman
16:03 - 16:16	Clinical trials in uveitis-The Reading Center Perspective	Marion Munk
16:16 - 16:29	Why previous uveitis trials often failed	James Rosenbaum
16:29 - 17:00	Round Table: What would be your ideal uveitis trial	Moderator: Philip Murray
THU, 29. November 2018
08:30 - 09:00	Registration (new participants)
	Biologic Agents for Uveitis
09:00 - 09:12	Definition of “Failure” under biologic drugs	Debra Goldstein
09:12 - 09:24	Biologics inducing uveitis	Manfred Zierhut
09:24 - 09:36	Side effects of biologics and biosimilars	Martin van Hagen
09:36 - 09:48	Off label biologics as the next step	Eric Suhler
09:48 - 10:15	Discussion
10:45 - 12:00	Case Reports	Chairs: Careen Lowder, Massimo Accorinti, Zohar Habot-Wilner
		Mystery Cases - Israeli Uveitis Group
12:00 - 12:30	Presentation of the best 5 Posters
	Uveitis in Immune Incompetent Patients
13:30 - 13:42	AIDS associated Uveitis in 2018	Jyotirmay Biswas
13:42 - 13:54	Role of CMV in immune incompetence	Alejandra dela Torre
13:54 - 14:06	Post-Transplantation-Lymphoproliferative disorders	Manfred Zierhut
14:06 - 14:18	Immune mediated ocular toxicity following the use of Immune Checkpoint Inhibitors for malignancy	Nida Sen
14:18 - 14:30	Carcinoma-associated Uveitis	Radgonde Amer

Rahmenprogramm

Tour to Jerusalem: Sunday, November 25th.Meeting Point&Time : 8AM leaves Dan Tel Aviv HotelTour includes: an English speaking guide, transportation from the Dan Tel Aviv Hotel, light meal + beverage.Price: $100 per person. Price based on participation of 15 people and may change according to the number of participants.Entry fees may be required. Monday 26/11 : 17.30-19.00 Welcome reception at the Dan hotel Tuesday 27/11 : 17.00 -19.00 Meeting c

alle	Gebühren ab 170,00 USD

 

Bitte wenden Sie sich für weitere Informationen direkt an den Veranstalter.

Keine Zertifizierung beantragt